Translational Biomedicine

  • ISSN: 2172-0479
  • Journal h-index: 18
  • Journal CiteScore: 5.91
  • Journal Impact Factor: 4.11
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • ResearchBible
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Secret Search Engine Labs
  • ResearchGate
Share This Page


Recent trends in Treatment of Acute Myloid Leukemia

Jabbour E

Acute myeloid leukemia (AML) is characterized by genetic aberrations and a variable response to the therapy has made the treatment of AML challenging. However, Hakim A et al. [1] in the review article discussed about the varied conventional treatments most likely the Chemotherapy, Irradiation and Haematopoietic stem cell transplantation (HSCT). Each of the conventional treatment comes with its own set of shortcomings/ limitations in terms of side effects, toxicity and efficacy respectively. Unfortunately, the overall 5-year survival from AML remains poor, particularly in adults and in the elderly. Nevertheless, the author has also provided insights into the novel therapies that needs to be developed within the conventional methods. Finally, the paper reviews the novel pathways where future interventions may have therapeutic potential.